SPRIX (ketorolac tromethamine) by Fresenius Kabi is clinical pharmacology pharmacodynamics ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (nsaid) that exhibits analgesic activity in animal models. First approved in 2010.
Drug data last refreshed 3d ago
SPRIX is a nasal spray formulation of ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthetase to provide analgesic and anti-inflammatory effects. It is indicated for moderate to severe acute pain including postoperative pain, low back pain, and ocular indications such as allergic conjunctivitis and post-operative anterior chamber inflammation. The S-enantiomer of ketorolac is responsible for therapeutic activity, with peak analgesic effect occurring within 2-3 hours.
Product is in LOE-approaching phase with minimal Part D spending and declining claims, indicating small-scale commercial teams and limited growth opportunities.
CLINICAL PHARMACOLOGY Pharmacodynamics Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits analgesic activity in animal models. The mechanism of action of ketorolac, like that of other NSAIDs, is not completely understood but may be related to prostaglandin…
Worked on SPRIX at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Comparison Of Ketorolac Tromethamine Versus Naproxen For Moderate to Severe Back Pain Treatment
Comparison Of Ketorolac Tromethamine Oral Drops Versus Naproxen For Moderate to Severe Back Pain Treatment
Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthalmic Solution Compared With Olopatadine Hydrochloride Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis
A 6 Month Study to Evaluate the Safety, Analgesic Efficacy of ACUVAIL™ (Ketorolac Tromethamine Ophthalmic Solution) 0.45%, in Post-PRK Corneal Wound Healing
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moSPRIX shows minimal job openings (zero linked positions) reflecting its mature, low-spending lifecycle status and limited commercial infrastructure. Roles available are likely concentrated in generic transition planning, compliance, and supply chain rather than growth-focused commercial teams.